The most relevant key opinion leader (KOL) in a therapeutic area isn’t necessarily the one with the longest publication list, the highest-profile institutional affiliation, or the most conference appearances. Yet those legacy signals have historically dictated how life sciences companies find experts and prioritize scientific engagement. Today, a broader understanding of expertise—one that accounts for digital reach, community referral networks, and real-world clinical behavior—combined with new AI-powered discovery capabilities, is changing the expert discovery process.
Defining the value of an MSL
First, what hasn’t changed is the importance of the relationships themselves. According to a 2026 study on how organizations define the value of a medical science liaison (MSL), the largest share of medical affairs respondents (27%) pointed to the ability to build and maintain strong relationships with KOLs—ranking it above deep scientific expertise (19%) and educating healthcare professionals (13%). But a relationship is only as valuable as the expert it’s built with, and finding the right experts is becoming a more nuanced exercise.
How do you define the value of an MSL within your organization?
| By their ability to build and maintain strong relationships with KOLs | 27% |
| It’s subjective based on what internal leadership thinks MSLs should be doing to contribute to company success | 24% |
| Through the quality and depth of scientific knowledge and expertise they provide | 19% |
| By their effectiveness in educating HCP about therapeutic areas and treatment options | 13% |
| Through their impact on patient outcomes and healthcare practices | 8% |
| Through their contribution to clinical research and insights that inform drug development and strategy | 6% |
| Other | 4% |
Figure 1 – How organizations define the value of medical science liaisons. Source: Data from Dyer et al., 2026, Table 5.
The short list had a ceiling
Traditional key opinion leader identification relies on reputation and relationships. Teams built lists from field input, citation counts, conference podiums, and the institutional memory of long-tenured MSLs. Influence was easier to see because it was concentrated. A few dozen academic leaders shaped how a disease was understood and treated.
The limits were just as clear. Lists were slow to update and overweighed seniority. They also sent every company after the same small group of people, which made those experts hard to reach and gave no one a competitive edge.
The science fragmented, and the expert landscape followed
Three shifts required expert discovery to evolve.
First, the volume of science exploded. PubMed now adds more than a million citations a year, and ClinicalTrials.gov lists more than half a million registered studies. No team can track that volume of research manually.
Second, therapeutic expertise became more specialized. Precision oncology, rare disease, and cell and gene therapy have created increasingly narrow areas of scientific and clinical focus. The most relevant expert for a particular program may be an emerging researcher with deep experience in a specific indication or therapeutic modality, rather than one of the most-cited names in the broader field.
Third, influence spread out. Researchers and academic physicians remain important, but they are part of a broader network that includes community-based clinicians who shape real-world practice, and digital opinion leaders, who build audiences on professional networks and social media, among other clinical leaders. A discovery approach focused exclusively on academic credentials and publication records can miss experts with meaningful clinical experience and professional influence.
Meanwhile, medical affairs grew from a support function into a strategic one, responsible for scientific exchange, evidence generation, and insights that inform the entire product lifecycle. Finding the right experts became central to that job.
Expert discovery became a data challenge
As the landscape grew, expert discovery increasingly required connecting information that had historically existed across separate sources, from publication databases and clinical trial records to Open Payments disclosures and conference activity.
Claims data added another dimension. Linking an expert to real-world treatment activity shows how many relevant patients they see and how they treat them, alongside what they’ve published. That’s the difference between an expert who studies a disease and one who also shapes how it’s managed in practice.
Data also made it possible to spot experts earlier in their careers. A researcher whose publication and trial activity is accelerating in a niche area may be a better long-term partner than an established name.
AI is changing the speed of discovery
AI is the latest shift, and it addresses some of the field’s most stubborn problems.
The first is identity. Expert data is messy. The same physician may appear under different name variations, institutions, and spellings across thousands of records. Machine learning can help resolve those records into a single, accurate profile, which is the foundation for everything else.
The second is search. Instead of filtering by keyword, teams can increasingly use natural language search to surface experts whose work is relevant. For example, a team can describe what it needs in plain terms, such as community oncologists in the Southeast who treat EGFR-mutant lung cancer and have published work on resistance, and start from a pre-filtered list of experts. Conversational refinement also lets MSLs narrow the results the way they would with a colleague: more trial experience or those with industry partnerships.
AI has limits, too. Its output is only as reliable as the data underneath it, and a confident summary built on incomplete or outdated records can send a team in the wrong direction. Tools that let users flag weak results and refine their queries help close that gap. Compliance requirements still apply. And the relationships at the center of medical affairs remain human work. The best use of AI is to give experienced teams better information faster, so they can spend their time on scientific exchange instead of research.
What modern KOL discovery requires
Today’s expert discovery must capture the full landscape, from academic leaders to community treaters and digital voices. It must show both scientific activity and real-world practice. And it must keep pace with a field that changes every month.
The Monocl Expert Suite from Definitive Healthcare gives medical affairs teams that view. Monocl ExpertInsight brings together the scientific activity of more than 17 million experts globally across all therapeutic areas, including publications, clinical trials, conference presentations, digital activity, and more, in profiles that update regularly. Monocl ExpertClaims connects those profiles to real-world treatment patterns from billions of medical claims.
The result is a faster, clearer path to the right experts, and stronger scientific relationships built on them. Sign up for a demo.